Tonix Pharmaceuticals Reveals Positive Data on TONMYA at Pain Medicine Conference

Treatment with TONMYA showed statistically significant improvements in pain relief, according to data presented at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Tonix Pharmaceuticals, a commercial-stage biotechnology company, presented data on its pain medication TONMYA (cyclobenzaprine HCl sublingual tablets) at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting in Salt Lake City, Utah. The data showed that treatment with TONMYA provided statistically significant improvements in pain relief compared to placebo.

Why it matters

The presentation of positive data on TONMYA at a major pain medicine conference is an important milestone for Tonix Pharmaceuticals as it works to commercialize this potential new treatment option for patients suffering from chronic pain conditions.

The details

Tonix Pharmaceuticals' data showed that TONMYA, the company's investigational cyclobenzaprine sublingual tablet, met the primary endpoint in a clinical trial, demonstrating statistically significant improvements in pain relief compared to placebo. The data was presented at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting in Salt Lake City, Utah.

  • The data on TONMYA was presented at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting, held in Salt Lake City, Utah.

The players

Tonix Pharmaceuticals Holding Corp.

A fully integrated, commercial biotechnology company that is developing TONMYA, an investigational cyclobenzaprine sublingual tablet, as a potential new treatment for chronic pain conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to present these positive data on TONMYA at the American Academy of Pain Medicine meeting, which represent an important milestone in the development of this investigational treatment for chronic pain.”

— Seth Lederman, Chief Executive Officer of Tonix Pharmaceuticals

What’s next

Tonix Pharmaceuticals plans to continue the clinical development of TONMYA and work towards potential regulatory approval and commercialization of the treatment.

The takeaway

The positive data on TONMYA presented at the pain medicine conference highlights the potential for this investigational treatment to provide a new option for patients suffering from chronic pain conditions, if it continues to demonstrate efficacy and safety in further clinical trials.